AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended November 2017; Provides Consolidated Earnings Guidance for the Six Months Ending February 2018 and Year Ending August 31, 2018
January 09, 2018 at 01:10 am EST
Share
AFC-HD AMS Life Science Co., Ltd. reported consolidated earnings results for the first quarter ended November 2017. For the quarter, the company reported net sales of JPY 3,844 million against JPY 3,608 million a year ago. Operating income was JPY 269 million against JPY 252 million a year ago. Ordinary income was JPY 260 million against JPY 248 million a year ago. Profit attributable to owners of parent was JPY 177 million or JPY 14.66 per basic share against JPY 106 million or JPY 8.80 per basic share a year ago.
The company provided consolidated earnings guidance for the six months ending February 2018 and year ending August 31, 2018. For the six months, the company expects net sales of JPY 7,700 million, operating income of JPY 620 million, ordinary income of JPY 600 million and profit attributable to owners of parent of JPY 350 million or JPY 28.90 per basic share.
For the year ending August 31, 2018, the company expects net sales of JPY 15,500 million, operating income of JPY 1,170 million, ordinary income of JPY 1,120 million and profit attributable to owners of parent of JPY 660 million or JPY 54.50 per basic share.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended November 2017; Provides Consolidated Earnings Guidance for the Six Months Ending February 2018 and Year Ending August 31, 2018